Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565862 | 0.78 | POLB (0.50) | LMNACYP2D6SRCMAPK1 | |
| Phenylglycine SCHEMBL30631311 | 0.78 | CYP2D6 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL2586024 | 0.78 | LMNA (0.48) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL11985509 | 0.78 | LMNA (0.48) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL8279099 | 0.78 | LMNA (0.48) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL5094452 | 0.77 | PTGS2 (0.48) | LMNAHIF1AKDM4ECYP2D6SRC | |
| Hydrochloric Acid SCHEMBL3954994 | 0.76 | ALDH1A1 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL7309314 | 0.75 | CYP2D6 (0.41) | LMNAKDM4ECYP2D6SRCALDH1A1 | |
| Phenylglycine SCHEMBL31402004 | 0.75 | CYP2D6 (0.56) | LMNAKDM4ECYP2D6SRCDPP4 | |
| Phenylglycine SCHEMBL159420 | 0.75 | CYP2D6 (0.56) | LMNAKDM4ECYP2D6SRCDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | LMNA 2528/4885ADRA2A 394/4885ADRA2C 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.